Brainsway Ltd. (BWAY) Form 6-K — Jun 29, 2026
BrainsWay announced positive real-world data from the largest study of its Deep TMS technology in patients with comorbid PTSD and Major Depressive Disorder. The retrospective study of 462 patients demonstrated that 83.5% experienced a response in PTSD symptoms with a 52% mean reduction in scores. Patients also saw significant improvements in depression, with a 66.6% response rate and a 27.3% remission rate. The findings were presented at a recent industry conference by Dr.
Key figures
- Total patients
- 462
- Ptsd response rate percent
- 83.5
- Ptsd score reduction percent
- 52
- Depression response rate percent
- 66.6
- Depression remission rate percent
- 27.3
- Depression score reduction percent
- 50
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.